CABA logo

Cabaletta Bio, Inc.

CABA
Healthcare|Biotechnology|US
$1.30
+0.02 (+1.56%)
DCF Value
$0.49
Tangible Book / Share
$1.52
Cash / Share
$1.60
Next Earnings Report
Mar 18, 2027
EPS est. -$0.32
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest May 4, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (5)

Jul 2028
Est. completion
P2P3Idiopathic Inflammatory Myopathy
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252n=74
Jan 2029
Est. completion
P1P2Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
NCT04422912n=40
Jul 2029
Est. completion
P2P3Systemic Sclerosis
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777n=37
Sep 2029
Est. completion
P1P2Generalized Myasthenia Gravis (gMG)
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
NCT06359041n=24
Dec 2029
Est. completion
P1P2Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297n=28

Recent Press Releases

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Nov 8, 2026 · GlobeNewsWire
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026 · GlobeNewsWire
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2026 · GlobeNewsWire
Cabaletta Bio to Participate in Upcoming Investor Conferences
Nov 3, 2026 · GlobeNewsWire
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2026 · GlobeNewsWire
Cabaletta Bio to Participate in Upcoming Investor Conferences
Sep 1, 2026 · GlobeNewsWire
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026 · GlobeNewsWire

SEC Filings (101)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 6, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Oct 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Sep 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 202610-QQuarterly reportDocumentIndex
Aug 13, 20268-KMaterial eventDocumentIndex
Aug 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 31, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 23, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
Jun 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 4, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 3, 20268-KMaterial eventDocumentIndex
Jun 1, 2026DEFA14AProxy / shareholder voteDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 14, 20268-KMaterial eventDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
May 4, 2026424B5Offering prospectusDocumentIndex
May 4, 20268-KMaterial eventDocumentIndex
Apr 28, 2026ARSAnnual report to holdersDocumentIndex
Apr 28, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 20, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 23, 2026S-8Employee stock planDocumentIndex
Mar 23, 202610-KAnnual reportDocumentIndex
Mar 23, 20268-KMaterial eventDocumentIndex
Feb 18, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex